Dominating the Multiple Sclerosis Market: Battle of The Big Three Biologicals

Author：  

Publisher： Adis International

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.1, Iss.3, 2004-01, pp. : 8-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study

By Bozikas V.P.   Anagnostouli M.C.   Petrikis P.   Sitzoglou C.   Phokas C.   Tsakanikas C.   Karavatos A.  

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Iss. 5, 2003-08 ,pp. : 835-839

Elsevier

Access to resources Recommend Favorite

Interferon neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

By Bertolotto A.   Malucchi S.   Milano E.   Castello A.   Capobianco M.   Mutani R.  

Immunopharmacology, Vol. 48, Iss. 2, 2000-07 ,pp. : 95-100

Elsevier

Access to resources Recommend Favorite

Natalizumab: multiple benefits in multiple sclerosis

By  

Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. : 9-11

Adis International

Access to resources Recommend Favorite

Role of Cannabinoids in Multiple Sclerosis

By Zajicek John P.  

CNS Drugs, Vol. 25, Iss. 3, 2011-03 ,pp. : 187-201

Adis International

Access to resources Recommend Favorite

Management of Children with Multiple Sclerosis

By Yeh E. Ann  

Pediatric Drugs, Vol. 14, Iss. 3, 2012-06 ,pp. : 165-177

Adis International

Access to resources Recommend Favorite